Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:MTCR

Metacrine (MTCR) Stock Price, News & Analysis

Metacrine logo

About Metacrine Stock (NASDAQ:MTCR)

Key Stats

Today's Range
$0.58
$0.59
50-Day Range
$0.55
$0.59
52-Week Range
$0.30
$0.59
Volume
83,889 shs
Average Volume
225,834 shs
Market Capitalization
$24.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Receive MTCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Metacrine and its competitors with MarketBeat's FREE daily newsletter.

MTCR Stock News Headlines

625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
See More Headlines

MTCR Stock Analysis - Frequently Asked Questions

Metacrine, Inc. (NASDAQ:MTCR) announced its earnings results on Thursday, May, 13th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $0.06.

Metacrine (MTCR) raised $84 million in an IPO on Wednesday, September 16th 2020. The company issued 6,500,000 shares at a price of $12.00-$14.00 per share. Jefferies, Evercore ISI and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Metacrine investors own include Outlook Therapeutics (OTLK), Plug Power (PLUG), Advanced Micro Devices (AMD), Salesforce (CRM), Fisker (FSR), Micron Technology (MU) and 9 Meters Biopharma (NMTR).

Company Calendar

Last Earnings
5/13/2021
Today
11/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MTCR
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Net Income
$-62,210,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.36 per share

Miscellaneous

Free Float
36,695,000
Market Cap
$24.75 million
Optionable
Not Optionable
Beta
-0.73
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

This page (NASDAQ:MTCR) was last updated on 11/15/2024 by MarketBeat.com Staff
From Our Partners